Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions

By Fischer Lars   Koch Arend   Schlegel Uwe   Koch Hans-Christian   Wenzel Rüdiger   Schröder Nicolas   Thiel Eckhard   Korfel Agnieszka  

Journal of Neuro-Oncology, Vol. 102, Iss. 1, 2011-03 ,pp. : 163-166

Springer Publishing Company

Access to resources Recommend Favorite

Carboplatin and bevacizumab for recurrent malignant glioma

By        

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 1082-1086

Spandidos Publications

Access to resources Recommend Favorite

Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report

By Nagane Motoo   Kobayashi Keiichi   Tanaka Masaki   Tsuchiya Kazuhiro   Shishido-Hara Yukiko   Shimizu Saki   Shiokawa Yoshiaki  

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 16-23

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

By  

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 157-e21

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients

By Ramiscal Judi Anne B.   Jatoi Aminah  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 578-581

Informa Healthcare

Access to resources Recommend Favorite